AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) shares saw strong trading volume on Friday . 11,653,000 shares were traded during mid-day trading, an increase of 764% from the previous session’s volume of 1,348,290 shares.The stock last traded at $17.95 and had previously closed at $17.95.
A number of equities research analysts have commented on the company. Jefferies Group reissued a “buy” rating and issued a $16.00 price objective on shares of AMAG Pharmaceuticals in a research note on Sunday, November 5th. ValuEngine cut AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. Cantor Fitzgerald reissued a “hold” rating and issued a $17.00 price objective on shares of AMAG Pharmaceuticals in a research note on Wednesday. Piper Jaffray Companies assumed coverage on AMAG Pharmaceuticals in a research note on Monday, October 23rd. They issued a “neutral” rating and a $18.00 price objective for the company. Finally, B. Riley reissued a “hold” rating and issued a $16.00 price objective on shares of AMAG Pharmaceuticals in a research note on Monday, January 29th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and three have assigned a buy rating to the company’s stock. AMAG Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $21.82.
The company has a market cap of $672.84, a PE ratio of -3.04 and a beta of 0.79. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.48 and a current ratio of 1.59.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.